Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Hexarelin

Examorelin, HEX

Quick Stats
Studies 233
Trials 61
Recruiting PHASE2 INTERVENTIONAL NCT06940011

Endocalyx in Treatment Resistent Hypertension

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The goal of this randomized, double-blind, placebo-controlled study is to assess whether the food supplement Endocalyx lowers blood pressure in patients with treatment resistant hypertension.

Detailed Description

During this intervention study, subjects will receive either a placebo or Endocalyx for 12 weeks. The main objective of this study is to assess whether the food supplement Endocalyx lowers blood pressure in patients with treatment resistant hypertension. Secondary objectives are: * Change from baseline in office blood pressure and 24-hour blood pressure profiles in subjects with treatment resistant hypertension. * To assess whether sodium intake, sex or kidney function modulates the effect of Endocalyx on blood pressure. * Change from baseline in total vessel density, perfused vessel density, proportion of perfused vessels and microvascular health score * To assess the effect of Endocalyx on total peripheral resistance. * The effect of Endocalyx on quality of life. * To estimate the potential impact of Endocalyx on long-term cardiovascular protection and health care costs.

Interventions

Name: Endocalyx Pro
Type: DIETARY_SUPPLEMENT
Description: 4 capsules once daily OR 2 capsules twice daily
Name: Placebo
Type: OTHER
Description: 4 capsules once daily OR 2 capsules twice daily

Primary Outcomes

Measure: Change from baseline in 24-hour systolic blood pressure
TimeFrame: 12 weeks
Description: We will perform an uncorrected analysis and an analysis that is corrected for the reported and measured changes in antihypertensive medication use.

Trial Information

NCT ID

NCT06940011

Status

Recruiting

Study Type

INTERVENTIONAL

Phases

PHASE2

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Last Updated

December 15, 2025